UPLC/Q‐TOF–MS‐based metabolomics evaluate the efficacy of oroxylin A against postmenopausal osteoporosis
Biomedical Chromatography · 2023-05 · 37 (5)
DOI: 10.1002/bmc.5609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 05.03.2023. Verfasst von Yansi Xian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Regenerative Medicine, Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, N…. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: General Program of Natural Science Foundation of Guangxi Province, National Key Program of Natural Science Foundation of State, Guangxi Science and Technology Base and Talent Special Project.
Abstract (Originalsprache)
Post‐menopausal osteoporosis (PMOP) is a common metabolic bone malady characterized by bone mass loss and bone microarchitectural deterioration; however, there is currently no effective drug for its management. According to our previous study, oroxylin A (OA) could effectively protect ovariectomized (OVX)‐osteoporotic mice from bone loss; however, its therapeutic targets are still unclear. From a metabolomic perspective, we studied serum metabolic profiles to discover potential biomarkers and OVX‐related metabolic networks, which could assist us to comprehend the impact of OA on OVX. Five metabolites were identified as biomarkers associated with 10 related metabolic pathways, including phenylalanine, tyrosine and tryptophan biosynthesis, and phenylalanine, tryptophan and glycerophospholipid metabolism. After OA treatment, the expression of multiple biomarkers changed, with lysophosphatidylcholine (18:2) being a major significantly regulated biomarker. Our study demonstrated that OA's effects on OVX are probably related to the regulation of phenylalanine, tyrosine and tryptophan biosynthesis. Our findings explain the role of OA against PMOP in terms of metabolism and pharmacology and provide a pharmacological foundation for OA treatment of PMOP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Key Laboratory of Regenerative Medicine, Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning, Guangxi, China.
- Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China.
- School of Clinical Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China.
ORCID-Profile: Fangming Song
Förderung
- General Program of Natural Science Foundation of Guangxi Province
- National Key Program of Natural Science Foundation of State
- Guangxi Science and Technology Base and Talent Special Project
- Nanning Qingxiu District Science and Technology Bureau Key Research and Development Projects
- Guangxi Scholarship Fund of Guangxi Education Department
- Youth Foundation of Natural Science Foundation of Guangxi Province
- Natural Science Foundation of Guangxi Province
- Specific Research Project of Guangxi for Research Bases and Talents
Zitieren
APA
Xian, Y., Nong, Y., Gao, Y., Su, Y., Lei, Z., Lian, H., Cheng, J., Liang, J., Feng, X., Liu, Z., Zhao, J., Zhao, T., Su, Z., Liu, Q., & Song, F. (2023). UPLC/Q‐TOF–MS‐based metabolomics evaluate the efficacy of oroxylin A against postmenopausal osteoporosis. Biomedical Chromatography, 37(5). https://doi.org/10.1002/bmc.5609
Vancouver
Xian Y, Nong Y, Gao Y, Su Y, Lei Z, Lian H, et al. UPLC/Q‐TOF–MS‐based metabolomics evaluate the efficacy of oroxylin A against postmenopausal osteoporosis. Biomedical Chromatography. 2023;37(5). doi:10.1002/bmc.5609
BibTeX
@article{Xian2023,
author = {Xian, Yansi and Nong, Yunyuan and Gao, Yijie and Su, Yuangang and Lei, Zhiqiang and Lian, Haoyu and Cheng, Jianwen and Liang, Jiamin and Feng, Xiaoliang and Liu, Zhijuan and Zhao, Jinmin and Zhao, Tongling and Su, Zhiheng and Liu, Qian and Song, Fangming},
title = {UPLC/Q‐TOF–MS‐based metabolomics evaluate the efficacy of oroxylin A against postmenopausal osteoporosis},
journal = {Biomedical Chromatography},
year = {2023},
volume = {37},
number = {5},
doi = {10.1002/bmc.5609}
}
EUVIMED